Alnylam Pharmaceuticals
ALNY
ALNY
817 hedge funds and large institutions have $59.2B invested in Alnylam Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 224 funds opening new positions, 279 increasing their positions, 222 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
26% more repeat investments, than reductions
Existing positions increased: 279 | Existing positions reduced: 222
2.27% less ownership
Funds ownership: 101.28% → 99.02% (-2.3%)
13% less call options, than puts
Call options by funds: $562M | Put options by funds: $649M
Holders
817
Holding in Top 10
13
Calls
$562M
Puts
$649M
Top Buyers
| 1 | +$1.01B | |
| 2 | +$483M | |
| 3 | +$391M | |
| 4 |
Jane Street
New York
|
+$381M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$330M |
Top Sellers
| 1 | -$1.24B | |
| 2 | -$858M | |
| 3 | -$548M | |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$479M |
| 5 |
Dodge & Cox
San Francisco,
California
|
-$357M |
